Trials / Completed
CompletedNCT04683406
A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A
A Randomized, Double-blind Phase III Clinical Study of ZSP1273 Tablets Compared With Placebo or Oseltamivir Patients With Acute Uncomplicated Influenza A
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 750 (actual)
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, randomized, double-blind, placebo-controlled, and active controlled clinical trial to assess the efficacy and safety of ZSP1273 tablets in the treatment of Acute Uncomplicated influenza A.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZSP1273 600 mg | 3 X 200-mg tablet taken orally |
| DRUG | Placebo to Oseltamivir | Placebo capsules matching oseltamivir2 X 75-mg |
| DRUG | Oseltamivir(oral) | 2 X 75-mg tablet taken orally |
| DRUG | Placebo to ZSP1273 | Placebo capsules matching ZSP1273 600 mg |
Timeline
- Start date
- 2020-12-28
- Primary completion
- 2023-04-01
- Completion
- 2023-05-16
- First posted
- 2020-12-24
- Last updated
- 2023-06-27
Locations
76 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04683406. Inclusion in this directory is not an endorsement.